Crossmark

Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s11739-026-04326-w

Published Online: 2026-03-31

Published Print: 2026-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Shuai

Tian, Fei

Yu, Lan

Li, Zhenhua

Hou, Jing

Wei, Yaochen

Cui, Haozhe

Cui, Shuqing

Ma, Xiangming https://orcid.org/0009-0005-4182-7244
Funding

Funding for this research was provided by:

Tangshan Science and Technology Bureau (B202302016)
License Information

Text and Data Mining valid from 2026-03-31

Version of Record valid from 2026-03-31
More Information

Article History

Received: 26 November 2025

Accepted: 11 March 2026

First Online: 31 March 2026

Declarations

:

: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript.

Document is current

Any future updates will be listed below